Duyuru • Feb 04
Borregaard ASA Proposes Ordinary Dividend for 2025, Payable on 27 April 2026 The Board of Directors of Borregaard ASA at a meeting on 3 February 2026 decided to propose an ordinary dividend for 2025 of NOK 4.75 per share to the Annual General Meeting. Dividend payment is estimated at NOK 474 million. The exact amount will depend on the number of treasury shares held at the date of the Annual General Meeting. No dividend will be paid on treasury shares held by the Borregaard Group. Provided that the traded shares are subject to ordinary settlement in the Norwegian Securities Register (VPS), shares acquired up to and including 16 April 2026 will carry the right to receive dividends, whereas shares that are acquired on and after 17 April 2026 will not carry the right to receive dividends. Subject to the decision of the Annual General Meeting, the dividend will be paid on 27 April 2026 to shareholders registered in the company’s shareholders’ register as evidenced in a transcript as of 20 April 2026. The share will be quoted ex dividend on 17 April 2026. The Annual General Meeting of Borregaard ASA will be held on Thursday 16 April 2026 at 1 p.m. (13:00 CEST) in Sarpsborg as a digital meeting. Duyuru • Sep 27
Borregaard Announces NOK 15 Million Award for Biomer Project to Develop Bio-Based Alternatives to Polycarboxylates The Norwegian Research Council has awarded NOK 15 million to support Borregaard’s innovation initiative, Biomer. The project aims to develop bio-based alternatives to polycarboxylates – fossil-based polymers commonly used in agriculture, industry, and household products. Polycarboxylates are known for their persistence in the environment and high carbon footprint. Through Biomer, Borregaard will develop new ways to turn Norwegian bioresources into greener polymers designed to replace these fossil-based materials. The project will leverage Borregaard’s advanced biorefinery in Sarpsborg and its expertise in wood chemistry to deliver sustainable solutions with significantly lower environmental impact. Board Change • Aug 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Jun 13
Borregaard ASA Announces Change in Group Executive Management, Effective August 1, 2025 Knut-Harald Bakke has been appointed EVP BioSolutions, effective 1 August 2025. He will also join the Group Executive Management on the same date. Bakke succeeds Tom Erik Foss-Jacobsen, who will assume the role of CEO on 1 August. Bakke currently serves as Director of Investor Relations and has previously held the position of Energy Director at Borregaard. Prior to joining the company in 2019, he held senior leadership roles at Norsk Hydro, where he was responsible for global energy market operations. He holds an MSc in Industrial Economics and Technology Management from the Norwegian University of Science and Technology (NTNU). Borregaard will initiate a process to appoint a new Director of Investor Relations. In the interim, CFO Per Bjarne Lyngstad will assume the responsibility from 1 August. Duyuru • Jan 29
Borregaard Asa Proposes Ordinary Dividend for 2024, Payable on 23 April 2025 At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2024 of NOK 4.25 per share. Ex-date: 11 April 2025. Record date: 14 April 2025. Payment date: 23 April 2025. Date of approval: 10 April 2025. Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: kr2.51 (vs kr2.38 in 3Q 2023) Third quarter 2024 results: EPS: kr2.51 (up from kr2.38 in 3Q 2023). Revenue: kr1.95b (up 14% from 3Q 2023). Net income: kr250.0m (up 5.5% from 3Q 2023). Profit margin: 13% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Duyuru • Sep 20
Borregaard ASA, Annual General Meeting, Apr 10, 2025 Borregaard ASA, Annual General Meeting, Apr 10, 2025. Buy Or Sell Opportunity • Jul 27
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.4% to €15.08. The fair value is estimated to be €18.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10.0% over the last 3 years. Earnings per share has grown by 9.1%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 41% in the next 2 years. Reported Earnings • Jul 18
Second quarter 2024 earnings released: EPS: kr2.45 (vs kr2.84 in 2Q 2023) Second quarter 2024 results: EPS: kr2.45 (down from kr2.84 in 2Q 2023). Revenue: kr1.95b (flat on 2Q 2023). Net income: kr244.0m (down 14% from 2Q 2023). Profit margin: 13% (down from 14% in 2Q 2023). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: kr2.01 (vs kr2.32 in 1Q 2023) First quarter 2024 results: EPS: kr2.01 (down from kr2.32 in 1Q 2023). Revenue: kr1.98b (up 6.8% from 1Q 2023). Net income: kr200.0m (down 13% from 1Q 2023). Profit margin: 10% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Upcoming Dividend • Apr 05
Upcoming dividend of kr3.75 per share Eligible shareholders must have bought the stock before 12 April 2024. Payment date: 22 April 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (4.6%). Reported Earnings • Mar 23
Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022) Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Declared Dividend • Feb 02
Dividend of kr3.75 announced Shareholders will receive a dividend of kr3.75. Ex-date: 12th April 2024 Payment date: 22nd April 2024 Dividend yield will be 24%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 01
Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022) Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Duyuru • Jan 31
Borregaard ASA Proposes Cash Dividend for 2023, Payable on 22 April 2024 At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2023 of NOK 3.75 per share. Ex-date: 12 April 2024. Record date: 15 April 2024. Payment date: 22 April 2024. Date of approval: 11 April 2024. Duyuru • Nov 29
Borregaard ASA (OB:BRG) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved from April 18, 2023. Borregaard ASA (OB:BRG) commences share repurchases on November 20, 2023, under the program mandated by the shareholders in the Annual General Meeting held on April 18, 2023. As per the mandate, the company is authorized to repurchase up to a total nominal value of NOK 10 million, corresponding to 10% of the share capital. The shares will be repurchased at a price not more than NOK 400 per share and no less than NOK 1 per share. The company may repurchase and dispose of its own shares to fulfil its incentive schemes. The repurchases will be used for amortization. The plan will be valid up to the 2024 Annual General Meeting, but no later than June 30, 2024.
On November 17, 2023, the company announced its intention of repurchasing 200,000 shares of its outstanding common stock. The repurchase of shares will be conducted in a period from November 20, 2023, up to and including December 20, 2023 at the latest. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: kr2.38 (vs kr2.40 in 3Q 2022) Third quarter 2023 results: EPS: kr2.38 (down from kr2.40 in 3Q 2022). Revenue: kr1.71b (down 2.2% from 3Q 2022). Net income: kr237.0m (flat on 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. New Risk • Jul 19
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 43% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 19
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr1.96b (up 13% from 2Q 2022). Net income: kr283.0m (up 12% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Germany. Buying Opportunity • Jun 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 2.2%. The fair value is estimated to be €19.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 11% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years. Reported Earnings • May 03
First quarter 2023 earnings released: EPS: kr2.32 (vs kr2.18 in 1Q 2022) First quarter 2023 results: EPS: kr2.32 (up from kr2.18 in 1Q 2022). Revenue: kr1.85b (up 15% from 1Q 2022). Net income: kr231.0m (up 6.5% from 1Q 2022). Profit margin: 13% (in line with 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Apr 12
Upcoming dividend of kr3.25 per share at 1.9% yield Eligible shareholders must have bought the stock before 19 April 2023. Payment date: 27 April 2023. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.5%). Reported Earnings • Feb 05
Full year 2022 earnings released: EPS: kr8.95 (vs kr6.95 in FY 2021) Full year 2022 results: EPS: kr8.95 (up from kr6.95 in FY 2021). Revenue: kr6.88b (up 19% from FY 2021). Net income: kr892.0m (up 29% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €16.32, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 15x in the Chemicals industry in Germany. Total returns to shareholders of 84% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €8.01 per share. Duyuru • Feb 02
Borregaard ASA Proposes Ordinary Dividend for 2022, Payable on 27 April 2023 At a meeting on 1 February 2023, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2022 of NOK 3.25 per share. Ex-date: 19 April 2023; Record date: 20 April 2023; Payment date: 27 April 2023; Date of approval: 18 April 2023. Recent Insider Transactions • Nov 10
Director recently bought €21k worth of stock On the 1st of November, John Ulvan bought around 2k shares on-market at roughly €14.17 per share. This transaction amounted to 75% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €142k more in shares than they have sold in the last 12 months. Reported Earnings • Oct 22
Third quarter 2022 earnings released: EPS: kr2.40 (vs kr2.12 in 3Q 2021) Third quarter 2022 results: EPS: kr2.40 (up from kr2.12 in 3Q 2021). Revenue: kr1.75b (up 23% from 3Q 2021). Net income: kr239.0m (up 13% from 3Q 2021). Profit margin: 14% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 16
Second quarter 2022 earnings released: EPS: kr2.52 (vs kr2.34 in 2Q 2021) Second quarter 2022 results: EPS: kr2.52 (up from kr2.34 in 2Q 2021). Revenue: kr1.74b (up 15% from 2Q 2021). Net income: kr252.0m (up 8.2% from 2Q 2021). Profit margin: 14% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • May 14
Insider recently bought €69k worth of stock On the 12th of May, Gisle Johansen bought around 11k shares on-market at roughly €6.43 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €228k more in shares than they have sold in the last 12 months. Reported Earnings • May 04
First quarter 2022 earnings released: EPS: kr2.18 (vs kr1.46 in 1Q 2021) First quarter 2022 results: EPS: kr2.18 (up from kr1.46 in 1Q 2021). Revenue: kr1.62b (up 14% from 1Q 2021). Net income: kr217.0m (up 49% from 1Q 2021). Profit margin: 13% (up from 10% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Apr 01
Upcoming dividend of kr5.00 per share Eligible shareholders must have bought the stock before 08 April 2022. Payment date: 21 April 2022. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (3.7%). Lower than average of industry peers (4.9%). Reported Earnings • Mar 19
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.1%, compared to a 5.1% growth forecast for the industry in Germany. Reported Earnings • Feb 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: kr6.95 (up from kr4.37 in FY 2020). Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 8.5%, compared to a 5.9% growth forecast for the industry in Germany. Recent Insider Transactions • Dec 08
Insider recently bought €69k worth of stock On the 6th of December, Kristin Misund bought around 10k shares on-market at roughly €6.90 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €299k more in shares than they have sold in the last 12 months. Reported Earnings • Oct 22
Third quarter 2021 earnings released: EPS kr2.12 (vs kr1.12 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr1.43b (up 13% from 3Q 2020). Net income: kr211.0m (up 88% from 3Q 2020). Profit margin: 15% (up from 8.9% in 3Q 2020). The increase in margin was driven by higher revenue. Recent Insider Transactions • Jul 30
General Counsel recently bought €132k worth of stock On the 29th of July, Rolf Heggen bought around 15k shares on-market at roughly €8.81 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €49k more in shares than they have sold in the last 12 months. Reported Earnings • Jul 16
Second quarter 2021 earnings released: EPS kr2.34 (vs kr1.01 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr1.51b (up 11% from 2Q 2020). Net income: kr233.0m (up 131% from 2Q 2020). Profit margin: 15% (up from 7.4% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 29
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr1.42b (up 3.4% from 1Q 2020). Net income: kr146.0m (up 43% from 1Q 2020). Profit margin: 10% (up from 7.4% in 1Q 2020). Executive Departure • Apr 20
Independent Chairman Jan Oksum has left the company On the 14th of April, Jan Oksum's tenure in the role of Independent Chairman ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months. Upcoming Dividend • Apr 08
Upcoming dividend of kr2.50 per share Eligible shareholders must have bought the stock before 15 April 2021. Payment date: 23 April 2021. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.5%). Reported Earnings • Mar 26
Full year 2020 earnings released: EPS kr4.37 (vs kr4.18 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Recent Insider Transactions • Mar 20
Insider recently bought €140k worth of stock On the 18th of March, Gisle Johansen bought around 15k shares on-market at roughly €9.32 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €15k more in shares than they bought in the last 12 months. Is New 90 Day High Low • Mar 03
New 90-day high: €16.66 The company is up 33% from its price of €12.48 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.31 per share. Is New 90 Day High Low • Feb 06
New 90-day high: €16.50 The company is up 37% from its price of €12.02 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.67 per share. Reported Earnings • Feb 05
Full year 2020 earnings released: EPS kr4.36 (vs kr4.17 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Analyst Estimate Surprise Post Earnings • Feb 05
Revenue beats expectations Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is expected to shrink by 1.2% compared to a 5.2% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Jan 21
New 90-day high: €14.98 The company is up 24% from its price of €12.10 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.03 per share. Is New 90 Day High Low • Jan 05
New 90-day high: €13.62 The company is up 8.0% from its price of €12.66 on 07 October 2020. The German market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.25 per share. Valuation Update With 7 Day Price Move • Nov 09
Market bids up stock over the past week After last week's 15% share price gain to kr13.00, the stock is trading at a trailing P/E ratio of 39.7x, up from the previous P/E ratio of 34.4x. This compares to an average P/E of 25x in the Chemicals industry in Germany. Total returns to shareholders over the past year are 48%. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of kr353.0m, down 23% from the prior year. Total revenue was kr5.22b over the last 12 months, up 3.5% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 22
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 0.3% at kr1.26b. Revenue is forecast to grow 2.3% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat. Is New 90 Day High Low • Oct 05
New 90-day high: €13.12 The company is up 47% from its price of €8.91 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.84 per share. Recent Insider Transactions • Sep 24
Board Observer recently sold €6.2k worth of stock On the 15th of September, Bente Klausen sold around 500 shares on-market at roughly €12.42 per share. In the last 3 months, there was an even bigger sale from another insider worth €124k. Insiders have been net sellers, collectively disposing of €85k more than they bought in the last 12 months. 
